Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by Analysts

Repligen Co. (NASDAQ:RGEN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $173.25.

A number of equities research analysts have commented on RGEN shares. Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. cut their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th.

Repligen Trading Up 2.6%

NASDAQ RGEN opened at $126.50 on Friday. The company has a fifty day simple moving average of $132.74 and a two-hundred day simple moving average of $145.06. The stock has a market cap of $7.11 billion, a P/E ratio of -248.04, a P/E/G ratio of 4.54 and a beta of 1.21. Repligen has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share. On average, analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP bought a new position in shares of Repligen during the 1st quarter valued at about $7,152,000. United Services Automobile Association acquired a new position in shares of Repligen during the 1st quarter worth approximately $461,000. Fred Alger Management LLC grew its holdings in Repligen by 21.6% in the 1st quarter. Fred Alger Management LLC now owns 437,037 shares of the biotechnology company's stock valued at $55,609,000 after buying an additional 77,530 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock valued at $18,067,000 after buying an additional 20,375 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock valued at $814,000 after buying an additional 6,238 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.